# Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

> **NCT01777321** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes zoster vaccine GSK1437173A

## Key facts

- **NCT ID:** NCT01777321
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-17
- **Primary completion:** 2013-10-10
- **Final completion:** 2014-11-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777321, "Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01777321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*